Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ

march 20, 2017

Gilead Sciences Canada, Inc. (Gilead Canada) commends the continued leadership of Quebec in the treatment of hepatitis C with the listing of EPCLUSA™ (sofosbuvir/velpatasvir) tablets effective on March 22, 2017.  EPCLUSA is the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.  This listing will support patients to access curative therapy in Quebec, and is a significant contribution to advancing Canada's efforts to achieving its World Health Organization commitment to eliminate hepatitis C by 2030.

Read more